comparemela.com
Home
Live Updates
FDA Approves Elfornithine for the Treatment of High-Risk Neu
FDA Approves Elfornithine for the Treatment of High-Risk Neu
FDA Approves Elfornithine for the Treatment of High-Risk Neuroblastoma in Adult, Pediatric Patients
This is the first FDA approval for a therapy intended to reduce the risk of relapse in patients with high-risk neuroblastoma.
Related Keywords
Breck Jones ,
Kristen Gullo ,
,